Akèy › Maladi selil fòs
Etid klinik pou Maladi selil fòs ap rekrite nan Etazini
107 etid pou Maladi selil fòs ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Atlanta, GA22 etid
- Washington, DC20 etid
- Memphis, TN18 etid
- Chicago, IL18 etid
- Philadelphia, PA15 etid
- Birmingham, AL14 etid
- New York City, NY13 etid
- St. Louis, MO12 etid
- Boston, MA10 etid
- Houston, TX10 etid
- Durham, NC10 etid
- Cincinnati, OH10 etid
- Pittsburgh, PA9 etid
- Columbus, OH9 etid
- Greenville, NC9 etid
- The Bronx, NY8 etid
- Charlotte, NC7 etid
- Los Angeles, CA7 etid
- Cleveland, OH7 etid
- Oakland, CA7 etid
- Baltimore, MD7 etid
- Nashville, TN6 etid
- Richmond, VA6 etid
- Indianapolis, IN5 etid
- Augusta, GA5 etid
- Detroit, MI5 etid
- Phoenix, AZ5 etid
- Jackson, MS5 etid
- Hartford, CT5 etid
- Milwaukee, WI4 etid
- Arlington, VA4 etid
- New Haven, CT4 etid
- Greenville, SC4 etid
- New Orleans, LA4 etid
- Rochester, NY3 etid
- Queens, NY3 etid
- Greenburgh, NY3 etid
- Edison, NJ3 etid
- Mobile, AL3 etid
- Newark, NJ3 etid
Pa eta
- Alabama16 etid
- Arizona5 etid
- Arkansas3 etid
- Connecticut7 etid
- Delaware6 etid
- Distrik Columbia10 etid
- Florid9 etid
- Georgia25 etid
- Illinois19 etid
- Indiana5 etid
- Kalifòni18 etid
- Lwizyàn5 etid
- Maryland17 etid
- Massachusetts10 etid
- Michigan9 etid
- Minnesota5 etid
- Mississippi5 etid
- Missouri13 etid
- New Jersey8 etid
- New York21 etid
- North Carolina18 etid
- Ohio22 etid
- Pennsylvania20 etid
- South Carolina6 etid
- Tennessee22 etid
- Texas11 etid
- Virginia9 etid
- Wisconsin4 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT04055818Blood Sampling for Research Related to Sickle Cell Disease
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 100 · Tout sèks · Mizajou Sep 29, 2026 · NCT00542230A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)
Ap rekriteFaz 3
Laj 12 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07656415A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Ap rekriteFaz 3
Laj 12 a 100 · Tout sèks · Mizajou Sep 28, 2026 · NCT06439082Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling
Ap rekriteFaz 1 bonè
Laj 18 a 100 · Tout sèks · Mizajou Sep 28, 2026 · NCT06313398Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 70 · Tout sèks · Mizajou Sep 28, 2026 · NCT03937817A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07187973A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
Ap rekriteFaz 3
Laj 2 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT06609226Dietary Intake and Dietary Behaviors in Adults With Sickle Cell Disease
Ap rekriteEtid obsèvasyon
Laj 18 a 120 · Tout sèks · Mizajou Sep 18, 2026 · NCT05170412A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
Ap rekriteFaz 3
Laj 12 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT06612268Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease
Ap rekriteFaz 1
Laj 18 a 65 · Tout sèks · Mizajou Sep 17, 2026 · NCT05904093Tocilizumab for Acute Chest Syndrome
Ap rekriteFaz 2
Laj 12 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT05640271Sickle Cell Disease Biofluid Chip Technology (SCD BioChip)
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 12 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT02824471Study to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individuals With Sickle Cell Disease
Ap rekriteEtid obsèvasyon
Laj 2 a 99 · Tout sèks · Mizajou Sep 11, 2026 · NCT06944067Assessing Molecular Mechanisms and Effects of Music Therapy in Youth With Sickle Cell Disease Using Single-cell RNA-sequencing
Ap rekrite
Laj 8 a 18 · Tout sèks · Mizajou Sep 10, 2026 · NCT07562451Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease
Ap rekriteFaz 1
Laj 8 a 17 · Tout sèks · Mizajou Sep 9, 2026 · NCT07226219A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
Ap rekriteFaz 1/2Volontè an sante akeyi
Laj 12 a 55 · Tout sèks · Mizajou Sep 9, 2026 · NCT06546670Early Screening and Treatment of Heart Complication in Sickle Cell Disease
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT07023666SCD Stem Cell Mobilization and Apheresis Using Motixafortide
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06442761Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors
Ap rekriteFaz 1/2
Laj 4 a 65 · Tout sèks · Mizajou Sep 4, 2026 · NCT07599176Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
Ap rekriteFaz 2
Laj 5 a 20 · Tout sèks · Mizajou Sep 2, 2026 · NCT07369024Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease
Ap rekriteFaz 1
Laj 18 a 90 · Tout sèks · Mizajou Aug 24, 2026 · NCT07566494Cerebrovascular Reactivity Measurements With High-Density Diffuse Optical Tomography
Ap rekriteVolontè an sante akeyi
Laj 6 a 70 · Tout sèks · Mizajou Aug 20, 2026 · NCT07776444A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
Ap rekriteFaz 2/3
Laj 12 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT05431088A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
Ap rekriteFaz 1/2Volontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT06481306Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.